Jain Rita 4

What Happened Rita Jain, a director of Avalo Therapeutics (AVTX), was granted a derivative award on March 31, 2026: 1,339 shares (stock options) with an exercise price of $12.13 each, representing a grant value of approximately $16,242. The award is reported as a derivative acquisition (code A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-01 (no late filing indicated).
• Instrument: Derivative award (options) for 1,339 shares at $12.13 per share; reported aggregate value ~$16,242.
• Vesting: The options were granted on March 31, 2026 and are 100% vested (footnote).
• Shares owned after transaction: Not specified in the filing.
• Transaction type: Award/grant (A) — not an immediate cash purchase or sale.

Context This was a compensation-related option grant to a director and not an open-market purchase. Because the options are fully vested on grant, they are immediately exercisable (exercise would require payment of the $12.13 per-share price and may trigger a separate Form 4 if exercised or if shares are later sold). Grants are routine for executive/director compensation and are factual disclosures of ownership changes rather than explicit buy/sell market signals.